Next Article in Journal
Patisiran Enhances Muscle Mass after Nine Months of Treatment in ATTRv Amyloidosis: A Study with Bioelectrical Impedance Analysis and Handgrip Strength
Next Article in Special Issue
Does the SARS-CoV-2 Spike Receptor-Binding Domain Hamper the Amyloid Transformation of Alpha-Synuclein after All?
Previous Article in Journal
The 2-Oxoglutarate Carrier Is S-Nitrosylated in the Spinal Cord of G93A Mutant hSOD1 Mice Resulting in Disruption of Mitochondrial Glutathione Transport
Previous Article in Special Issue
Synucleins: New Data on Misfolding, Aggregation and Role in Diseases
 
 
Article
Peer-Review Record

Gamma-Synuclein Dysfunction Causes Autoantibody Formation in Glaucoma Patients and Dysregulation of Intraocular Pressure in Mice

Biomedicines 2023, 11(1), 60; https://doi.org/10.3390/biomedicines11010060
by Tatiana A. Pavlenko 1, Andrei Y. Roman 2, Olga A. Lytkina 2, Nadezhda E. Pukaeva 2,3, Martha W. Everett 3, Iuliia S. Sukhanova 2,3, Vladislav O. Soldatov 4, Nina G. Davidova 1, Natalia B. Chesnokova 1, Ruslan K. Ovchinnikov 2,3 and Michail S. Kukharsky 2,3,*
Reviewer 1:
Reviewer 2: Anonymous
Biomedicines 2023, 11(1), 60; https://doi.org/10.3390/biomedicines11010060
Submission received: 3 December 2022 / Revised: 18 December 2022 / Accepted: 23 December 2022 / Published: 27 December 2022

Round 1

Reviewer 1 Report

The manuscript by Pavlenko et al is focused on the unravelling of the role of gamma-synuclein in dysregulation of intraocular pressure and glaucoma. The authors shown that gamma-synuclein can modulate the mechanism of pathology of glaucoma through effect on intraocular pressure via interaction with catecholamines (dopamine). This is interesting and novel manuscript and I have only minor comments. 

1. Abstract. "γ-synuclein is an aggregation-prone protein involved in neurodegenerative diseases." However, the role of this form of synuclein in the mechanism of neurodegeneration is disputable compare to alpha-synuclein. Considering this this abstract would be better without this statement.

2. Figure legends 2 and 3 needs some additional explanation.  

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

This is a well written and organized manuscript, in which, the authors demonstrated the presence of autoantibodies against γ-synuclein in 20% of the patients in the study.

 

  

 

Specific suggestions/comments raised by the reviewer:

 

Line 22: “glaucoma-related physiological changes” or “glaucoma-related pathophysiological changes” Please specify.

 

Line 85: Render “antihypertensive” as “ocular hypotensive”

 

Line 93: Provide an alternate rendering for “optical cornea”

 

Lines 134 – 135: It was previously established that general anesthesia does not affect the level of IOP in both γ-KO and WT mice. Previously established by whom and when…

 

What is the sample size of the experimental animals?

 

Line 158: Rearrange the order of these numbers.

 

Line 297: The authors should elaborate on these other forms of glaucoma in which autoantibodies against γ-synuclein are expressed as the manuscript appears to only address POAG.

 

Line 296: Can you offer any explanation as to why only 1 in 5 individuals with POAG had autoantibodies against γ-synuclein?

 

 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop